About 100,000 people in the U.S. are affected by sickle cell disease, a disproportionate percentage of which are black or Hispanic. About one in 13 black or African Americans have sickle cell trait and are at risk for having a child with the disease. The inherited blood disorder leads to many medical complications and shortens the life spans of people affected by about 20-30 years. For people living with the disease, early intervention and access to care are vital for their long-term prognosis, physically and psychologically. HICOR is partnering with NHLBI, Emmes, and University of Washington to develop models that will estimate the clinical and economic benefits of cures for sickle cell disease. The goal is to clarify the potential long-term benefits of promising new curative therapies.